Advertisement
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Hiroshi Ureshino, Takero Shindo, Hidenori Tanaka, Hiroh Saji and Shinya Kimura
DOI: 10.1158/1535-7163.MCT-20-0336 Published January 2021

Abstract

Treatment-free remission (TFR) is one of the therapeutic goals for patients with chronic phase chronic myeloid leukemia (CML-CP). Although previous reports indicated that antitumor immunity contributes to TFR, its determinants are still unclear. We previously reported that allelic polymorphisms of killer immunoglobulin-like receptors (KIR) and human leukocyte antigens (HLA) are associated with achievement of deep molecular response (DMR) in patients with CML-CP. Here, we examined the association between TFR and polymorphisms of KIRs and HLAs in patients who discontinued tyrosine kinase inhibitors (TKI). Seventy-six patients were enrolled, and their KIR and HLA polymorphisms and natural killer (NK) cell activation status were investigated as previously described. Overall, 33 patients discontinued TKIs, and 21 of 33 achieved TFR [63.6%; 95% confidence interval (CI), 44.9%–77.5%] at 1 year. Multivariate analysis revealed that male sex (HR, 0.157; 95% CI, 0.031–0.804; P = 0.003) and HLA-A*02:01, *11:01, or *24:02 (HR, 6.386; 95% CI, 1.701–23.980; P = 0.006) were associated with TFR. Patients who achieved DMR and discontinued TKIs exhibited higher NK cell activation status than those who did not. By contrast, there were no significant differences in NK cell activation status between the patients who achieved TFR and those who experienced molecular relapse. These results suggest NK cell activation status contributes to achievement of DMR, whereas T-cell–mediated immunity contributes to TFR in patients with CML-CP.

This article is featured in Highlights of This Issue, p. 1

Introduction

ABL tyrosine kinase inhibitors (TKI) markedly improve the prognosis of patients with chronic phase chronic myeloid leukemia (CML-CP; ref. 1). Several clinical trials investigating treatment-free remission (TFR) after TKI discontinuation revealed that approximately 40%–60% of the patients who achieved a durable deep molecular response (DMR) during TKI treatment show sustained molecular remission after TKI discontinuation (2–6). Male sex (2), long-term TKI treatment (2, 6, 7), deeper molecular remission status (undetectable BCR-ABL1 transcript levels) before TKI discontinuation (8, 9), and an increased number of natural killer (NK) cells (4, 10) and a reduced number of CD4-cells (11) were favorable prognostic factors for TFR in the patients with CML-CP. Recently, BCR-ABL1 transcriptional detection methods using the digital PCR (dPCR) have emerged (12) and may be a useful tool for prediction of TFR in patients with CML-CP (13, 14). Although TFR is now the therapeutic goal of CML-CP, the factors that predict TFR remain unclear because it has not been analyzed comprehensively.

Sensitive BCL-ABL1 transcriptional detection methods (15) can detect residual leukemic cells in patients who achieve TFR. Given that residual leukemic cells exist in these patients, the host immune system appears to prevent CML development or relapse mediated by residual leukemic cells (16); therefore, it is reasonable to assume that cancer immunosurveillance plays an important role in achievement of TFR. The human immune system comprises innate and adaptive arms, which provide functional diversity (16, 17). T cells are major components of the adaptive immune system; these antigen-specific lymphocytes undergo clonal expansion and induce target cell death. Allogenic stem cell transplantation (allo-SCT) has been used as a curative treatment for patients with CML-CP in the past. The beneficial effects of this treatment can be partly attributed to donor T-cell–mediated graft-versus-leukemia effects. Indeed, leukemia relapse is more common in CML cases undergoing T-cell–depleted allo-SCT (18). BCR-ABL1 chimeric proteins induce expansion of clonal human leucocyte antigen (HLA)-restricted cytotoxic T cells (CTL), which may control CML (19). Furthermore, the magnitude of HLA-restricted CTL depends on the HLA allele (20, 21). In particular, HLA-A*02:01, *24:02, and *11:01 can drive expansion of HLA-restricted cytotoxic T cells in patients with CML (22). Thus, T-cell immunity, possibly enhanced by particular polymorphisms, is indispensable for immune reaction in CML.

NK cells play a pivotal role in innate immunity against virally infected or malignant cells by discharging cytotoxic granules. Patients with newly diagnosed CML-CP show NK cell dysfunction; however, TKI treatment can restore NK cell function in patients with CML-CP (23), leading to molecular remission. Furthermore, CML recipients showing early recovery of NK cell populations after allo-SCT have a more favorable outcome (24), and the number of NK cells positively correlates with achievement of TFR (4, 25). Taken together, these findings suggest that NK cell–mediated immunity also plays an important role in CML.

NK cell activity is determined by the balance between activating and inhibitory signals induced via surface receptors (26). Among these, KIRs are the most polymorphic molecules that bind to MHC class I molecules [known as the human leukocyte antigen (HLA) system in human; ref. 27]. HLAs also harbor abundant polymorphisms; thus, the combination of KIRs and HLAs determines the magnitude of NK cell responses in patients with autoimmune diseases and cancers (28). Recently, next-generation sequencing (NGS) revealed that KIRs harbor abundant allelic polymorphisms that affect NK cell activity (29) as well as HLAs. We reported previously that allelic polymorphisms of KIRs and HLAs are associated with achievement of DMR in patients with CML-CP (30). We also found that high NK (11) and low CD4+ T-cell counts (4) were favorable prognostic factors for TFR in these patients.

However, it is unclear which cell-mediated immune response, T-cell or NK, is more important for achieving TFR in patients with CML, and no detailed analysis of polymorphisms in KIRs and HLAs in patients with CML after discontinuing TKIs [only KIR genotyping or haplotyping analysis has been reported; refs. 31, 32] has been undertaken. Therefore, we aimed to undertake subgroup analysis to examine the association between TFR and HLA and KIR polymorphisms in patients who discontinued TKIs, based on our previous analysis of DMR and KIRs/HLAs (30).

Patients and Methods

Patients

Patients with Philadelphia chromosome-positive CML-CP (n = 76) who were treated with TKIs (imatinib, dasatinib, or nilotinib) between April 2002 and August 2017 at Saga University Hospital were enrolled. NGS of DNA from the patients (n = 76) was performed to evaluate the association between KIR/HLA polymorphisms and TFR. CML was diagnosed according to the World Health Organization classification of myeloid neoplasms and acute leukemia (33). Baseline patient characteristics were obtained from hospital records; these included general characteristics (age and sex), laboratory data (complete cell counts, blast counts, and percentage of eosinophils and basophils), molecular diagnosis (BCR-ABL1 transcript levels), and spleen size. Written informed consent was obtained from all patients before registration, as required by the Declaration of Helsinki. This study was approved by the institutional review board of Saga University (UMIN-CTR, ID: R000020356).

Evaluation of therapeutic effects

Response criteria were defined according to BCR–ABL1 mRNA transcript levels [as measured by real time quantitative-PCR (RQ-PCR)] adjusted to the international reporting scale (IS), and/or using the transcription-mediated amplification (TMA) method. A major molecular response (MMR) was defined as ≤0.1% (on the IS) or a BCR-ABL1 transcript level of <50 copies/0.5 μg RNA (TMA). MR4.0 was defined as ≤0.01% (on the IS) or undetectable BCR-ABL1 (TMA). MR4.5 was defined as ≤0.0032% (on the IS). DMR was defined as MR4.0 or a deeper response, and molecular relapse was defined as loss of DMR at two consecutive time points or loss of MMR at a single time point. The TMA method for quantification of BCR-ABL1 transcripts was the only method approved by the national insurance body of Japan until June 2015 (34), and before the implementation of international standards (11, 35) in our institute. This method was used only to confirm DMR before TKI discontinuation. Monitoring after TKI discontinuation was assessed by RQ-PCR, as stipulated by international standards. RQ-PCR analyses were done every 3 months during the consolidative TKI treatment (patients with durable DMR before TKI discontinuation), every month for the first year after TKI discontinuation, and every 3 months after the second year.

Criteria for TKI discontinuation

TKI was discontinued in patients who enrolled in TKI stop clinical trials (n = 12) or in those not in clinical trials (n = 21) who attended Saga University Hospital. Patients in clinical trials discontinued TKIs according to individual study protocols (4, 7, 11). Patients not in clinical trials discontinued TKIs if they so wished 20 patients met the criteria for TFR as a treatment option according to the European Society for Medical Oncology guidelines (36); one patient experienced adverse events after durable DMR after at least 3 years of TKI treatment.

Genotyping of KIR and HLA

Allelic genotyping of HLA and KIR genes was performed by NGS of DNA samples using Illumina MiSeq technology, as previously described (30).

Antibodies and flow cytometry

The following monoclonal antibodies were used to identify their respective antigens: FITC–anti-CD3 (OKT3, TONBO Biosciences); PE-Cy7–anti-CD56 (HCD56) and Pacific Blue–anti-CD107a (H4A3; both from BioLegend); and APC-Cy7–anti-CD16 (3G8) and V450–IFNγ (B27; both from BD Biosciences). Fixation and permeabilization buffer sets (Thermo Fisher Scientific) were used to stain IFNγ. Stained samples were assessed using a FACSVerse cytometer (BD Biosciences) and data were analyzed using FlowJo software (Tree Star).

Assessment of NK cell activity

The activation status of NK cells was evaluated by flow cytometry analysis of CD107a degranulation and intracellular IFNγ secretion by CD3−CD16+CD56+ NK cells, as previously described (30). The experiments were performed at the next visit after registration in the study. The correlation between NK cell activation and achievement of DMR and/or TFR was examined.

Statistics analysis

Cumulative incidence probabilities were calculated using the Kaplan–Meier method and differences were analyzed using the log-rank test. Cox's proportional hazard model was used to evaluate TFR, and two-sided P values <0.05 were considered statistically significant. The Mann–Whitney U test was used to determine statistically significant differences between two groups or variables. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University), a graphical user interface for R.

Results

Patient characteristics

A total of 33 of 76 CML-CP patients discontinued TKIs. The median follow-up time was 7.61 years (range, 4.37–16.30 years); the median age was 65 years (range, 39–86 years); 17 patients were male and 16 were female; and 14, 12, and seven patients had low, intermediate, and high Sokal scores, respectively. The first-line TKI was imatinib in 17 cases, dasatinib in 11, and nilotinib in five. The TKI used before discontinuation was imatinib in nine cases, dasatinib in 17, and nilotinib in seven; eight patients who began treatment with imatinib were switched to second-generation TKIs due to suboptimal responses or adverse events. Overall, 21 of 33 patients achieved TFR [63.6%; 95% confidence interval (CI), 44.9%–77.5%] at 1 year (Fig. 1). The detailed clinical characteristics are summarized in Supplementary Table S1.

Figure 1.
Figure 1.

Treatment-free remission in 33 patients.

Male sex is associated with successful achievement of TFR in patients with CML-CP

Univariate analysis of the clinical characteristics for TFR (including sex, age, Sokal-risk score, use of first-line TKIs, TKI used before discontinuation, DMR time before TKI discontinuation and duration of TKI treatment) identified male sex as a significant prognostic variable for a lower likelihood of molecular relapse [hazard ratio (HR), 0.141; 95% CI, 0.031–0.645; P = 0.012; Table 1; Fig. 2A], whereas age, Sokal-risk score, type of TKI, and TKI treatment duration had no effect.

View this table:
Table 1.

Univariate analysis to identify clinical characteristics responsible for molecular relapse.

Figure 2.
Figure 2.

Treatment-free remission according to sex (A), HLA profile (B), and HLA-A heterozygosity (C).

Patients with CML-CP who lack HLA-A*02:01, *24:02, or *11:01 are at increased risk of molecular relapse

Univariate analysis of KIR and HLA profiles revealed that KIR genotype, KIR allele type, KIR and HLA licensing status, KIR3DL1 expression levels, KIR3DL1 and HLA-Bw interaction avidity [determined by measuring the strength of interactions (strong, weak or no interaction) between KIR3DL1 (high, low or null) and HLA-B (HLA-Bw4-80T, 80I or Bw6); e.g., KIR3DL1high binds HLA-Bw4-80I more strongly than HLA-Bw4-80T as previously described; refs. 30, 37], and HLA-C did not affect the incidence of molecular relapse (Table 2). TFR in patients with HLA-Bw6 was lower than in patients with HLA-Bw4-80I (45.5%; 95% CI, 16.7–70.7; vs. 78.9%; 95% CI, 53.2–91.4; P = 0.043; HR, 3.496; 95% CI, 0.980–12.48; P = 0.054) and patients lacking HLA-A*02:01, *24:02, or *11:01 were more likely to experience molecular relapse (HR, 5.546; 95% CI, 1.885–20.092; P < 0.001; Table 2; Fig. 2B; Supplementary Table S2). Furthermore, homozygous (HLA-A*02:01, *24:02, or *11:01) individuals tended to experience less molecular relapse than heterozygous individuals [TFR; homozygous (n = 12), 91.7% (95% CI, 53.9–98.8); heterozygous (n = 14), 64.3% (95% CI 34.3–83.3); P = 0.12; Table 2; Fig. 2C]. These results indicate that HLA-A profile plays an important role in TFR, and the degree of heterozygosity may be correlated with TFR in patients with CML-CP.

View this table:
Table 2.

Univariate analysis to identify killer immunoglobulin-like receptors (KIR) and human leukocyte antigens (HLA) responsible for molecular relapse.

Sex and HLA profile are significantly associated with achievement of TFR in patients with CML-CP with multivariate analysis

Multivariate analysis identified male sex (HR, 0.157; 95% CI, 0.031–0.804; P = 0.003) and HLA-A*02:01, *11:01, or *24:02 (HR, 6.386; 95% CI, 1.701–23.980; P = 0.006) as independent favorable prognostic factors for TFR in patients with CML (Table 3), indicating that sex-specific or HLA-restricted T-cell–mediated immune responses may be involved in TFR.

View this table:
Table 3.

Multivariate analysis to identify variables responsible for molecular relapse.

NK cell activation plays a pivotal role in achievement of DMR but not TFR

Previously, we reported that the degree of NK cell activation contributes to achievement of MR4.0. Here, we found that patients who discontinued TKIs (achievement of durable deep molecular remission; n = 20) exhibited higher levels of CD107a degranulation (Fig. 3A) and secretion of IFN-γ (Fig. 3B) than the patients who did not (n = 22). By contrast, there were no significant differences in CD107a degranulation and IFN-γ secretion between patients who achieved TFR (n = 13) and those who experienced molecular relapse (n = 8, Fig. 3C and D). These results suggest that NK cell activation contributes to achievement of DMR but not TFR.

Figure 3.
Figure 3.

Evaluation of NK cell activation status. CD107a degranulation (A) and IFN-γ secretion (B) by NK cells isolated from patients according to TKI discontinuation status [TKI discontinuation (n = 20); no discontinuation (n = 22)]. CD107a degranulation (C) and IFN-γ secretion (D) by NK cells from patients according to treatment-free remission status (treatment-free remission, n = 13; molecular relapse, n = 8).

Discussion

Here, we identified that sex (male) and HLA polymorphisms (HLA-A*02:01, *24:02, and *11:01) were associated with TFR in the patients with CML-CP. The finding that male sex is a favorable predictive factor for TFR is consistent with the results of the STIM trial (2); however, the majority of TKI discontinuation studies suggest that a patient's sex does not affect TFR (2, 4–6), even in clinical trials using a sensitive dPCR method to detect BCR-ABL1 (13, 14). Immune cell populations (38) and immune responses (39) differ in males and females; indeed, female sex is a favorable prognostic factor for DMR in the patients who are treated with TKIs (30, 40, 41). Anyway, further investigation is still needed to conclude whether patient sex is involved in achievement of TFR.

Immune cell profiles, especially the magnitude of NK cell responses modulated by TKIs (42) in patients with CML-CP may determine the responses of TKIs treatment (23, 43). Previously, we reported that NK cell immune responses contribute to achievement of DMR (MR4.0) in patients with CML-CP; this finding was associated with several favorable KIR allelic haplotypes and with NK cell activation status (30). Here, the patients with durable DMR exhibited higher NK cell activation (CD107a degranulation and secretion of IFNγ) than those with less molecular responses, indicating that NK cell activation with favorable KIR alleles (30) is necessary for achievement of durable DMR in the patients with CML-CP. By contrast, we found no differences in NK cell activation status and KIR polymorphisms between patients with TFR and those with molecular relapse, which indicates that different immune responses contribute to achievement of DMR and maintenance of TFR.

The results of prior clinical observational studies of associations between KIRs and hematological malignancies have often been inconsistent, due to patient heterogeneity (44, 45) or HLA-associated factors such as the association between downregulation of HLAs and immune escape (46). The small cohort of patients in our study could have resulted in several factors canceling the clinical impact of KIR polymorphisms in patients with CML-CP and preventing them from achieving TFR. We have begun an analysis examining the impact of KIR and HLA polymorphisms in a larger cohort.

HLA-restricted antigen presentation is assumed to be important for the induction of T-cell immune responses in patients with CML (22). Antigen-specific cytotoxic T cells are more strongly induced in patients with HLA-A*02:01, *24:02 or *A11:01, whereas they are less induced in patients with other HLA alleles (20, 21); we therefore focused on HLA-A*02:01, *24:02, and *11:01. Our results indicate the HLA profile, that is, A*02:01, *24:02, or *11:01 in particular, may be an independent prognostic factor for achieving TFR. However, these three HLA alleles did not affect achievement of DMR in patients with CML-CP (30). T cells are major components of adaptive immunity (16) and HLA-restricted cytotoxic T cells (CTLs) that recognize BCR-ABL1 are detectable in patients with CML-CP (19). The magnitude of HLA-restricted CTL depends on the HLA allele (20, 21). In particular, HLA-A*02:01, *24:02, and *11:01 can drive expansion of HLA-restricted cytotoxic T cells (CTLs), which may be involved in long-lasting adaptive immune responses (47), and successful achievement of TFR. We previously reported that T-cell profiles were associated with successful achievement of TFR (11). These results suggest HLA-restricted T-cell–immune responses may also be important for achieving TFR (unlike at induction therapy) in patients with CML-CP. Peptide vaccination to induce T-cell immune response against CML may have the potential to increase achievement of TFR (48).

Previous reports indicated that an increase in the number NK cells is associated with achievement of DMR (4, 10), suggesting that NK cells might also have a role in achieving TFR. On the basis of the results of this article, we would like to propose that the strong molecular responses of undetectable BCR-ABL1 transcript levels (8, 9) are associated with TFR. Therefore, a higher number of NK cells immediately before TKI discontinuation may be associated with TFR (4, 10), through higher probability of DMR. Currently, we assume that T cells, not NK cells, contribute to TFR, but this will require further verification.

Several surrogate markers for successful achievement of TFR have been investigated (49). Lower BCR-ABL1 transcript levels detected by digital PCR (13, 14), e14a2 BCR-ABL1 transcript type (50), longer TKI treatment duration, time of DMR, presence of withdrawal syndrome, a deeper molecular response, a lower Sokal score, and interferon α treatment before TKI administration may be associated with a favorable TFR (49). However, different study designs have generated inconsistent data; therefore, further investigations are needed to identify factors that consistently favor achievement of TFR.

Our results indicate that NK cell–mediated innate immunity plays a pivotal role in the achievement of DMR in patients with CML-CP, whereas T-cell–mediated adaptive immunity contributes to TFR, but this will require further confirmation in a future study. Indeed, we are now examining KIR and HLA polymorphisms in a larger cohort patients enrolled in the DADI (4), DOMEST (7), and first-line DADI (11) trials. Moreover, we are also undertaking a further prospective TFR trial to investigate the gene expression profiles and the NK and T-cell subpopulations responsible for successful achievement of TFR. Further understanding of the role of KIR and HLA polymorphisms in patients with CML-CP could help optimize treatment strategies (e.g., duration of consolidation phase) for the achievement of successful TFR.

Authors' Disclosures

S. Kimura reports grants and personal fees from Bristol-Myers Squibb, Pfizer, and Novartis Pharmaceuticals outside the submitted work. No disclosures were reported by the other authors.

Authors' Contributions

H. Ureshino: Data curation, formal analysis, funding acquisition, investigation, writing-original draft, writing-review and editing. T. Shindo: Conceptualization, writing-original draft, writing-review and editing. H. Tanaka: Writing-review and editing. H. Saji: Supervision. S. Kimura: Conceptualization, supervision, funding acquisition, writing-review and editing.

Acknowledgments

This work was supported by research grants from JSPS KAKENHI (19K17860; to H. Ureshino) and JSPS KAKENHI (17K09908; to S. Kimura).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Footnotes

  • Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

  • Mol Cancer Ther 2021;20:142–9

  • Received April 27, 2020.
  • Revision received August 31, 2020.
  • Accepted October 6, 2020.
  • Published first October 20, 2020.

References

  1. 1.↵
    1. Hochhaus A,
    2. Larson RA,
    3. Guilhot F,
    4. Radich JP,
    5. Branford S,
    6. Hughes TP,
    7. et al.
    Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017;376:917–27.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Mahon FX,
    2. Réa D,
    3. Guilhot J,
    4. Guilhot F,
    5. Huguet F,
    6. Nicolini F,
    7. et al.
    Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029–35.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Rousselot P,
    2. Charbonnier A,
    3. Cony-Makhoul P,
    4. Agape P,
    5. Nicolini FE,
    6. Varet B,
    7. et al.
    Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32:424–30.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Imagawa J,
    2. Tanaka H,
    3. Okada M,
    4. Nakamae H,
    5. Hino M,
    6. Murai K,
    7. et al.
    Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2015;2:e528–35.
    OpenUrl
  5. 5.↵
    1. Hochhaus A,
    2. Masszi T,
    3. Giles FJ,
    4. Radich JP,
    5. Ross DM,
    6. Gómez Casares MT,
    7. et al.
    Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 2017;31:1525–31.
    OpenUrl
  6. 6.↵
    1. Saussele S,
    2. Richter J,
    3. Guilhot J,
    4. Gruber FX,
    5. Hjorth-Hansen H,
    6. Almeida A,
    7. et al.
    Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 2018;19:747–57.
    OpenUrlCrossRef
  7. 7.↵
    1. Fujisawa S,
    2. Ueda Y,
    3. Usuki K,
    4. Kobayashi H,
    5. Kondo E,
    6. Doki N,
    7. et al.
    Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int J Clin Oncol 2019;24:445–53.
    OpenUrl
  8. 8.↵
    1. Takahashi N,
    2. Nishiwaki K,
    3. Nakaseko C,
    4. Aotsuka N,
    5. Sano K,
    6. Ohwada C,
    7. et al.
    Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica 2018;103:1835–42.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Takahashi N,
    2. Tauchi T,
    3. Kitamura K,
    4. Miyamura K,
    5. Saburi Y,
    6. Hatta Y,
    7. et al.
    Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol 2018;107:185–93.
    OpenUrl
  10. 10.↵
    1. Rea D,
    2. Henry G,
    3. Khaznadar Z,
    4. Etienne G,
    5. Guilhot F,
    6. Nicolini F,
    7. et al.
    Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica 2017;102:1368–77.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Kimura S,
    2. Imagawa J,
    3. Murai K,
    4. Hino M,
    5. Kitawaki T,
    6. Okada M,
    7. et al.
    Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol 2020;7:e218–25.
    OpenUrl
  12. 12.↵
    1. Alikian M,
    2. Whale AS,
    3. Akiki S,
    4. Piechocki K,
    5. Torrado C,
    6. Myint T,
    7. et al.
    RT-qPCR and RT-digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia. Clin Chem 2017;63:525–31.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Nicolini FE,
    2. Dulucq S,
    3. Boureau L,
    4. Cony-Makhoul P,
    5. Charbonnier A,
    6. Escoffre-Barbe M,
    7. et al.
    Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients. Clin Cancer Res 2019;25:6606–13.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Bernardi S,
    2. Malagola M,
    3. Zanaglio C,
    4. Polverelli N,
    5. Dereli Eke E,
    6. D'Adda M,
    7. et al.
    Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med 2019;8:2041–55.
    OpenUrl
  15. 15.↵
    1. Ross DM,
    2. Branford S,
    3. Seymour JF,
    4. Schwarer AP,
    5. Arthur C,
    6. Yeung DT,
    7. et al.
    Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515–22.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Ureshino H,
    2. Shindo T,
    3. Kimura S
    . Role of cancer immunology in chronic myelogenous leukemia. Leuk Res 2020;88:106273.
    OpenUrl
  17. 17.↵
    1. Hoffmann J,
    2. Kafatos F,
    3. Janeway C,
    4. Ezekowitz R
    . Phylogenetic perspectives in innate immunity. Science 1999;284:1313–8.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Apperley JF,
    2. Mauro FR,
    3. Goldman JM,
    4. Gregory W,
    5. Arthur CK,
    6. Hows J,
    7. et al.
    Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol 1988;69:239–45.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Yotnda P,
    2. Firat H,
    3. Garcia-Pons F,
    4. Garcia Z,
    5. Gourru G,
    6. Vernant JP,
    7. et al.
    Cytotoxic T-cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998;101:2290–6.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Sakamoto S,
    2. Matsueda S,
    3. Takamori S,
    4. Toh U,
    5. Noguchi M,
    6. Yutani S,
    7. et al.
    Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele. Cancer Sci 2017;108:598–603.
    OpenUrl
  21. 21.↵
    1. Yashiki S,
    2. Fujiyoshi T,
    3. Arima N,
    4. Osame M,
    5. Yoshinaga M,
    6. Nagata Y,
    7. et al.
    HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T-cell leukemia: the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8+ cytotoxic lymphocytes. AIDS Res Hum Retroviruses 2001;17:1047–61.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Bilich T,
    2. Nelde A,
    3. Bichmann L,
    4. Roerden M,
    5. Salih HR,
    6. Kowalewski DJ,
    7. et al.
    The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood 2019;133:550–65.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Hughes A,
    2. Clarson J,
    3. Tang C,
    4. Vidovic L,
    5. White DL,
    6. Hughes TP,
    7. et al.
    CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 2017;129:1166–76.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Savani BN,
    2. Rezvani K,
    3. Mielke S,
    4. Montero A,
    5. Kurlander R,
    6. Carter CS,
    7. et al.
    Factors associated with early molecular remission after T-cell–depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006;107:1688–95.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Hekim C,
    2. Ilander M,
    3. Yan J,
    4. Michaud E,
    5. Smykla R,
    6. Vähä-Koskela M,
    7. et al.
    Dasatinib changes immune cell profiles concomitant with reduced tumor growth in several murine solid tumor models. Cancer Immunol Res 2017;5:157–69.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Vivier E,
    2. Raulet DH,
    3. Moretta A,
    4. Caligiuri MA,
    5. Zitvogel L,
    6. Lanier LL,
    7. et al.
    Innate or adaptive immunity? The example of natural killer cells. Science 2011;331:44–9.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Parham P
    . MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005;5:201–14.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Parham P,
    2. Moffett A
    . Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013;13:133–44.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Norman PJ,
    2. Hollenbach JA,
    3. Nemat-Gorgani N,
    4. Marin WM,
    5. Norberg SJ,
    6. Ashouri E,
    7. et al.
    Defining KIR and HLA class I genotypes at highest resolution via high-throughput sequencing. Am J Hum Genet 2016;99:375–91.
    OpenUrlCrossRef
  30. 30.↵
    1. Ureshino H,
    2. Shindo T,
    3. Kojima H,
    4. Kusunoki Y,
    5. Miyazaki Y,
    6. Tanaka H,
    7. et al.
    Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML. Cancer Immunol Res 2018;6:745–54.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Caocci G,
    2. Martino B,
    3. Greco M,
    4. Abruzzese E,
    5. Trawinska MM,
    6. Lai S,
    7. et al.
    Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Exp Hematol 2015;43:1015–8.
    OpenUrl
  32. 32.↵
    1. Dumas P,
    2. Bérard E,
    3. Bréal C,
    4. Dulucq S,
    5. Réa D,
    6. Nicolini F,
    7. et al.
    Killer immunoglobulin—like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment—free remission. Cancer Med 2019;8:4976–85.
    OpenUrl
  33. 33.↵
    1. Arber DA,
    2. Orazi A,
    3. Hasserjian R,
    4. Thiele J,
    5. Borowitz MJ,
    6. Le Beau MM,
    7. et al.
    The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391–405.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Langabeer SE,
    2. Gale RE,
    3. Harvey RC,
    4. Cook RW,
    5. Mackinnon S,
    6. Linch DC
    . Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia 2002;16:393–9.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Hochhaus A,
    2. Baccarani M,
    3. Silver RT,
    4. Schiffer C,
    5. Apperley JF,
    6. Cervantes F,
    7. et al.
    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966–84.
    OpenUrl
  36. 36.↵
    1. Cortes J,
    2. Rea D,
    3. Lipton JH
    . Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol 2019;94:346–57.
    OpenUrl
  37. 37.↵
    1. Ureshino H,
    2. Shindo T,
    3. Sano H,
    4. Kubota Y,
    5. Ando T,
    6. Kidoguchi K
    . Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation. Int J Hematol 2020;111:733–8.
    OpenUrl
  38. 38.↵
    1. Phan MT,
    2. Chun S,
    3. Kim SH,
    4. Ali AK,
    5. Lee SH,
    6. Kim S,
    7. et al.
    Natural killer cell subsets and receptor expression in peripheral blood mononuclear cells of a healthy Korean population: reference range, influence of age and sex, and correlation between NK cell receptors and cytotoxicity. Hum Immunol 2017;78:103–12.
    OpenUrl
  39. 39.↵
    1. Voysey M,
    2. Barker CIS,
    3. Snape MD,
    4. Kelly DF,
    5. Trück J,
    6. Pollard AJ
    . Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells. Vaccine 2016;34:1657–64.
    OpenUrl
  40. 40.↵
    1. Branford S,
    2. Yeung DT,
    3. Ross DM,
    4. Prime JA,
    5. Field CR,
    6. Altamura HK,
    7. et al.
    Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013;121:3818–24.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Breccia M,
    2. Colafigli G,
    3. Molica M,
    4. De Angelis F,
    5. Quattrocchi L,
    6. Latagliata R,
    7. et al.
    Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib. Br J Haematol 2016;173:945–6.
    OpenUrl
  42. 42.↵
    1. Najima Y,
    2. Yoshida C,
    3. Iriyama N,
    4. Fujisawa S,
    5. Wakita H,
    6. Chiba S,
    7. et al.
    Regulatory T-cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—the final results of the D-first study. Leuk Res 2018;66:66–72.
    OpenUrl
  43. 43.↵
    1. Brück O,
    2. Blom S,
    3. Dufva O,
    4. Turkki R,
    5. Chheda H,
    6. Ribeiro A,
    7. et al.
    Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia 2018;32:1643–56.
    OpenUrl
  44. 44.↵
    1. Venstrom JM,
    2. Pittari G,
    3. Gooley TA,
    4. Chewning JH,
    5. Spellman S,
    6. Haagenson M,
    7. et al.
    HLA-C–dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012;367:805–16.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Schetelig J,
    2. Baldauf H,
    3. Heidenreich F,
    4. Massalski C,
    5. Frank S,
    6. Sauter J,
    7. et al.
    External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails. Blood 2020;135:1386–95.
    OpenUrl
  46. 46.↵
    1. Christopher MJ,
    2. Petti AA,
    3. Rettig MP,
    4. Miller CA,
    5. Chendamarai E,
    6. Duncavage EJ,
    7. et al.
    Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med 2018;379:2330–41.
    OpenUrlPubMed
  47. 47.↵
    1. Jo T,
    2. Noguchi K,
    3. Hayashi S,
    4. Irie S,
    5. Hayase R,
    6. Shioya H,
    7. et al.
    Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib. Oncol Lett 2018;15:2935–8.
    OpenUrl
  48. 48.↵
    1. Qazilbash MH,
    2. Wieder E,
    3. Thall PF,
    4. Wang X,
    5. Rios R,
    6. Lu S,
    7. et al.
    PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 2017;31:697–704.
    OpenUrl
  49. 49.↵
    1. Ureshino H,
    2. Kamachi K,
    3. Kimura S
    . Surrogate markers for treatment-free remission in patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2020;S2152–650:30338–4.
    OpenUrl
  50. 50.↵
    1. D’Adda M,
    2. Farina M,
    3. Schieppati F,
    4. Borlenghi E,
    5. Bottelli C,
    6. Cerqui E,
    7. et al.
    The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Cancer 2019;125:1674–82.
    OpenUrl
Back to top
View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Hiroshi Ureshino, Takero Shindo, Hidenori Tanaka, Hiroh Saji and Shinya Kimura
Mol Cancer Ther January 1 2021 (20) (1) 142-149; DOI: 10.1158/1535-7163.MCT-20-0336
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement